End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.12 CNY | +3.88% | +8.07% | -17.07% |
Apr. 26 | Aier Eye Hospital Group Co., Ltd. Announces Profit Distribution Proposal for 2023 | CI |
Apr. 26 | Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 47% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.95 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.97 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.07% | 16.21B | B+ | ||
+3.60% | 12.44B | B | ||
+5.64% | 11.58B | B+ | ||
+4.63% | 10.79B | B+ | ||
+25.55% | 8.26B | B | ||
-0.21% | 7.68B | A- | ||
+22.18% | 7.06B | D | ||
+5.27% | 6.67B | B- | ||
+52.00% | 4.66B | - | ||
-5.36% | 4.25B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300015 Stock
- Ratings Aier Eye Hospital Group Co., Ltd.